RxDoctor Payments DataLook up a doctor →

Steven Rousey, MD

Hematology & Oncology · Edina, MNNPI 1427027119

Payments from drug & device makers

$1,159,883in general payments, 2019–2025

Across 471 payments — averaging $2462.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Seagen Inc.$903K
  • Janssen Research & Development, LLC$196K
  • Merck$29K
  • Pfizer$26K
  • AstraZeneca$5K
  • AbbVie$120
  • plus $97 from 3 others

What the payments were for

  • Grants$12050%
  • Food & beverage$219%
  • Education$9741%

General payments by program year

20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,159,883 in reported general payments places this provider in the 90th percentile of 193 hematology & oncology providers in Minnesota.

See all hematology & oncology providers in Minnesota

Medicare billing

Part B allowed, 2024
$2,173,600
Medicare patients
323
Services billed
66,637

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib44$676,747
BrukinsaZanubrutinib43$632,438
CalquenceAcalabrutinib Maleate39$579,282
Lenalidomide40$528,493
RevlimidLenalidomide30$417,130
TagrissoOsimertinib Mesylate24$385,852
InlytaAxitinib23$303,803
OrserduElacestrant Hcl11$245,838
LorbrenaLorlatinib12$197,772
ImbruvicaIbrutinib11$164,675
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5013$87,331
OrgovyxRelugolix20$50,219
Abiraterone Acetate44$38,880
XareltoRivaroxaban63$38,795
Imatinib Mesylate61$9,792

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Inlyta, Lorbrena, Eliquis$26,382$1,186,79992 claims
AstraZenecaCalquence, Tagrisso$5,399$965,13463 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 193 hematology & oncology providers in Minnesota.

Other hematology & oncology in Edina

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →